Kornimate/medical-research-clean huggingface dataset:
mineralocorticoid use in covid-19 patients

Conditions: COVID-19; ARDS

Summary: there is a considerable variability in aldosterone levels between individuals, and this may explain the wide variability in disease severity among those infected so we designed a pilot study to test for the safety and efficacy of fludrocortisone addition to standard of care in hospitalised covid-19 patients.

many studies have shown involvement of renin-angiotensin-aldosterone system (raas) in pathophysiology of covid-19. there is a considerable variability between people infected with sars-cov-2 virus in terms of severity. at pathophysiological level there are variable degrees of increased capillary permeability with resultant fluid leak. we hypothesize that the physiological response to overcome this fluid leak mainly involves stimulation of mineralocorticoid (aldosterone) pathway. hence; those with defective mineralocorticoid response are at high risk for disease complications. aldosterone secretion capacity is affected by many factors whether physiological (age, sex, ethnicity and pregnancy) or pathological (e.g. smoking); this is reflected in wide differences (regarding aldosterone levels) between groups of people depending on these factors. these variations in mineralocorticoid capacity between groups of people may explain why some certain groups are at high risk for severe disease while others are at a lower risk. so we designed this pilot study to assess safety and efficacy of mineralocorticoid, in the form of fludrocortisone, as a potential treatment for covid-19 by its addition to dexamethasone in hospitalized covid-19 patients.

Eligibility criteria:
inclusion criteria: * male and non-pregnant female patients 18 years of age or older * diagnosed with covid-19 pneumonia as per local guidelines * oxygen saturation (sao2) of 93 % or less while they were breathing ambient air. exclusion criteria: * a physician decision that involvement in the trial will not be in the patient's best interest, presence of any condition that would not allow the protocol to be followed safely. * known allergy or hypersensitivity to fludrocortisone. * known severe liver or kidney disease, uncontrolled hypertension, diabetes mellitus and peptic ulcer disease. * hypokalemia (serum potassium of less than 3.5 meq/l) * use of medications that are contraindicated with fludrocortisone and that could not be replaced or stopped during the trial period.

Keywords: fludrocortisone mineralocorticoid covid-19 ards aldosterone
the remote family support programs for eating disorders

Conditions: Eating Disorders

Summary: eating disorders are serious mental health disorders associated with high levels of mortality, disability, physical and psychological morbidity, and impaired quality of life. family members who spend the majority of their time with patients of eating disorders experience heavy psychological burden. remote family support programs consist of interpersonal psychotherapy and family psychoeducation. this study aimed to examine the effectiveness of a remote family support program for eating disorders in an rct (randomized controlled trial). the specific objective was to conduct a small pilot rct of the remote family support program (n=28) compared with tau (n=28).


Eligibility criteria:
inclusion criteria: * the research participants are parents of patients who have been diagnosed with an eating disorder by a physician or have symptoms of an eating disorder; parents may or may not be related by blood. * the abos score measured by the research participants at enrollment is over 8 points. * patient age at enrollment ranged from 12 to 29 years. * the patient has lived with their parents at the time of participating in this study and is expected to live with them during the investigation period. * patients may or may not undergo treatment. * patients with other psychiatric comorbidities are included. * participants with other psychiatric comorbidities are included. * if multiple family members (e.g., parents) participated in this program, the primary participant is determined, and that person becomes the target research participant. * willingness to provide informed consent and comply with the trial protocol. exclusion criteria: * the participants cannot read or write in japanese * the participants cannot use the zoom meeting system * researcher of this study and their families

Keywords: family support, interpersonal psychotherapy
imaging response to immunotherapy and radiation therapy in patients with liver metastases

Conditions: Liver Metastases

Summary: patients will be imaged with mre at the time of the rt planning mri, prior to the induction of rt and immunotherapy. research imaging will be in addition to standard imaging studies performed at time points consistent with the standard of care (at the time of the rt planning mri and the first clinical follow-up). an additional mre exam will be performed at the end of treatment outside the standard of care imaging.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of solid cancers with the presence of one or more liver metastases * minimum metastasis diameter ≥ 2 cm * planning to receive radiation therapy with immunotherapy * willingness to participate in mandatory imaging studies at mayo clinic rochester exclusion criteria: * contraindications for mri including claustrophobia, pace maker, metal implants, aneurism clips * patients who are not able to consent
sleepflextm treatment of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this study is to evaluate the safety and effectiveness of the sleepflex program for treatment of mild to moderate osa


Eligibility criteria:
inclusion criteria: * age 21 years and older * mild to moderate osa, defined as ahi \>10 - 30 events/hour, documented by polysomnogram or home sleep apnea test within 180 days prior to study enrollment * central or mixed disordered breathing events (≤25% of total number of events) * unable to tolerate or decline positive airway pressure therapy * body mass index ≤32 kg/m2 * able to protrude tongue ≥20 mm beyond maxillary incisors * absence of markedly enlarged tonsils, defined as 3+ or 4+ according to the brodsky classification * no uncontrolled sleep disorder other than osa such as narcolepsy, chronic insomnia, restless legs syndrome, or rem behavior disorder * absence of excessive daytime sleepiness, defined by epworth sleepiness scale score \>10 * no uncontrolled nasal obstruction * absence of moderate to severe mandibular insufficiency * no previous surgery involving the oral cavity or pharynx other than tonsillectomy * no previous radiation therapy to the head and neck * no known neurologic, cardiac (other than hypertension controlled with a single medication), pulmonary, renal, hepatic, or psychiatric disorders * no psychiatric diagnoses other than treated depression or mild anxiety * stable medication regimen for ≥1 month * no acute illness or infection * ownership of personal smartphone with ios or android operating system * no known hypersensitivity to any material of the sleepflex devices exclusion criteria: * unwilling or unable to provide informed written consent in english * pregnancy, breastfeeding, or plans to become pregnant * smoker (tobacco or recreational drugs) in the past month * alcohol consumption, averaged over the previous month, greater than 2 alcoholic beverages per day * significant vision or hearing problems * unwilling or incapable of returning for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires * any other reason the investigator determines as being unfit for study participation
10-year follow-up of the ponto wide-implant

Conditions: Survival of the Ponto Wide Implant

Summary: the goal of this single center, prospective study is to investigate the survival of the ponto wide implant at least 10 years after implantation. secondary objectives are: 1. to determine the amount and causes of implant loss and implant and/or abutment removal. 2. to establish the stability of the implant. 3. to assess skin complications. 4. to investigate daily usage and the number of hours of use of the sound processor. 5. to determine the quality of life. during a check-up of the implant at the outpatient clinic, the skin around the implant will be assessed, the stability of the implant will be measured, and the patient will be asked to complete two questionnaires.

patients who participated in the previous studies concerning the ponto wide implant from oticon (3 years after implantation) will be approached. if consent is given, they will be added to the database of the already completed studies, and new data will be stored in the same database. the patients were already pseudonymized in the previous studies, and the database is secured with a code that is only accessible to individuals directly involved in the research

Eligibility criteria:
inclusion criteria: * implantation with ponto wide implant (diameter 4.5 mm, length 4.0 mm) * ten or more years of post-operative follow-up. * valid informed consent exclusion criteria: * no specific exclusion criteria have been set for the study.

Keywords: implant survival ponto wide implant oticon 10 years deafness hearing loss hearing disorders
pilot study to image the esophagus using a secm tethered endoscopic capsule

Conditions: Healthy; Barrett's Esophagus; Gastric Acid Reflux

Summary: the goal of this research is to test the imaging quality of the modified, larger diameter, tethered spectrally encoded confocal microscopy (secm) capsule in healthy subjects, subjects with barrett's esophagus (be), and subjects with gastroesophageal reflux disease (gerd).

36 subjects including 12 healthy volunteers, 12 patients with barrett's esophagus and 12 with gastroesophageal reflux disease will be enrolled and asked to swallow the secm hitec capsule. the subjects will be awake and unsedated. the capsule is attached to a string like tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus using natural propulsive force called peristalsis. as the capsule progresses through the esophagus, multiple images of the esophagus are acquired in real time to be analyzed later.

Eligibility criteria:
inclusion criteria: * subjects must be 1) a healthy volunteer (18 years or older), or 2) a subject with prior diagnosis of be (18 years or older), or 3) a subject with prior diagnosis of gerd (18 years or older). * and subject must be able to give informed consent. * and subject must eat no solid foods for 8 hours before the procedure and only clear liquids for 2 hours before the procedure. exclusion criteria: * subjects with any history of or known upper gastrointestinal strictures * or subjects with a history of crohn's disease, * or subjects with difficulty swallow

Keywords: barrett's gerd capsule secm
evaluation of the use of the colli-pee device to collect first-void urine for molecular detection of stis

Conditions: Sexually Transmitted Diseases, Bacterial

Summary: study objectives: * to evaluate the usability of the colli-peetm device to collect first-void urine for nucleic acid detection of neisseria gonorrhoeae, chlamydia trachomatis, trichomonas vaginalis and mycoplasma genitalium. * to collect feedback on the easiness of use and the willingness of future use of the colli-peetm device.

study population: the colli-pee study is a sub-study of the be-prep-ared study (eudract number: 2015-000054-37). all participants who participate in the be-prep-ared study will be asked to participate in this sub-study. study design: participants who agree to be included in this study will be asked to collect first-void urine using the colli-peetm device the day after the baseline, month 6, month 12 and month 18 visit. they will be asked to send the urine container back to itm using regular mail. in addition they will also be asked to complete a small questionnaire concerning the easiness of use and the willingness of future use of the colli-peetm device at the enrolment visit and final visit of the be-prep-ared study.

Eligibility criteria:
inclusion criteria: * participating in the be-prep-ared study * willing to collect first-void urine the next day and to send it back to itm using regular mail. exclusion criteria: * none

Keywords: colli-pee sti first-void urine
effect of intrauterine injection of hcg on clinical pregnancy outcome in repeated implantation failure patients

Conditions: Infertility

Summary: repeated implantation failure（rif） is a insurmountable bottleneck in assisted reproductive technology, many studies have considered that the cause of two-thirds of implantation failure is the decreased endometrial receptivity. after exclude some major local immune factors(nk,cd138 cells) and implantation window out of phase, there are still a part of patients infertile .human chorionic gonadotropin (hcg) is an early pre-implantation signal molecule secreted by the embryo, it can promote endometrial proliferation, increase blood flow and promote embryonic adhesion and inhibit self-regulated apoptosis of trophoblast cells. previous studies showed that: intrauterine injection of hcg before embryo transfer can improve clinical outcomes in ivf/intracytoplasmic sperm injection(icsi). but some studies found that the intrauterine injection of hcg can not significantly improve the success rate of blastocyst transfer, and the reason may be the intrauterine injection of hcg time is too late to significantly increase the implantation rate. would ahead of intrauterine injection of hcg be more effective? thus, the patients of repeated implantation frozen embryo cycle according to the random principle accepted two kinds of transplants ways: ①intrauterine injection of hcg before blastocyst transfer; ②blastocyst transfer. try to understand whether intrauterine injection of hcg can significantly improve the clinical pregnancy rate of blastocyst transfer in repeated implantation failure patients.


Eligibility criteria:
inclusion criteria: * repeated implantation failure patients: ≥ 3 times ivf-embryo transfer failed to help pregnancy (biochemical or non-pregnant) * age ≤36 years old * normal histopathological stage (+5-7) * endometrial nk cell \<4.5% * 0 endometrial cd138 positive cell * natural cycle frozen embryo transfer * frozen blastocysts (≥4bc) embryos ≥ 1 exclusion criteria: * scar uterus (diverticulum or incision false lumen after cesarean section) * intrauterine adhesions * untreated hydrosalpinx * adenomyosis (endometrial displacement) * endometritis * uterine fibroids compress the endometrium
proximal versus distal adductor canal blocks for total knee arthroplasty

Conditions: Post-Operative Pain

Summary: this study is designed to evaluate pain control of continuous adductor canal blocks placed proximally versus distally within the canal. the investigators hypothesize that there will be similar pain control between both groups.

this study is a non-inferiority trial designed to determine whether placement of a continuous block within the adductor canal has a substantial impact on pain following total knee arthroplasty. our primary outcome to determine this difference will be opioid consumption within the first day following surgery. secondary outcomes will include: pain scores, quadriceps strength, and distance ambulated during physical therapy.

Eligibility criteria:
inclusion criteria: * unilateral total knee arthroplasty * asa physical status i-iii * \>18 years old * non-pregnant * consent to participate in the study exclusion criteria: * refusal to participate * \<18 years old * chronic opioid use * localized infection pregnancy pre-existing coagulopathy allergy to ultrasound gel or local anesthetics contraindication to or refusal of spinal anesthetic
correlation between urine uacr and postoperative neurocognitive disorder in elderly patients with non-cardiac surgery

Conditions: Postoperative Cognitive Dysfunction; Delirium

Summary: this study intends to evaluate the relationship between urinary albumin/creatinine ratio and postoperative neurocognitive impairment in elderly non-cardiac surgery patients. the results of the study are to identify risk factors, screen high-risk populations to improve clinical evidence, early detection and early treatment.and reducing the burden of pncd on patients and their families, hospitals and public resources.


Eligibility criteria:
inclusion criteria: * non-cardiac surgery patients; * age is greater than or equal to 60 years old; ③han nationality, mother tongue is chinese; ④the mmse score:illiteracy is greater than or equal to 17 points, primary school is greater than or equal to 20 points, higher secondary school is more than 24 points; ⑤the people signed informed consent. exclusion criteria: * the diagnosis of preoperative delirium； * the diagnosis unstable hypertension（such as：pheochromocytoma or aortic dissection）； ③severe chronic obstructive pulmonary disease or congestive heart failure； ④severe liver and kidney dysfunction;

Keywords: postoperative cognitive dysfunction delirium uacr
effect of liraglutide on blood glucose control in japanese subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in japan. the aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in japanese subjects with type 2 diabetes. liraglutide or placebo is administered by injection once daily in the evening. the trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. treatment allocation is random with equal chance of being assigned to each group.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy * 7.0 % =\< hba1c \< 10.0 % * body mass index (bmi) \< 30.0 kg/m\^2 exclusion criteria: * subjects treated with thiazolidinediones or insulin * subjects with any serious medical conditions
healthy outcomes for muscle with exercise in t1d

Conditions: Diabetes Mellitus, Type 1

Summary: over 300,000 people in canada suffer from type 1 diabetes (t1d), a chronic condition whose incidence rate has been increasing in canada every year by 5.1% (higher than the global average). while exogenous insulin injections allow those with t1d to live, it is not a cure, and those with t1d develop severe complications (kidney failure, cardiovascular disease). strategies to regress the development of these complications, minimize healthcare system burden, and save the lives of canadians are urgently needed. undertaking regular exercise is an obvious strategy for those with t1d and has many well-established health benefits. despite these benefits, adults with t1d exercise less frequently due to fear of severe hypoglycemia and a lack of knowledge of effective exercise strategies. adding to this complexity, the investigators have recently shown that males and females elicit differential impairments in skeletal muscle metabolism in response to t1d. these differences may extend to the peripheral microvasculature and may lead to sexual dimorphism in the health benefits of exercise for those with t1d. ultimately, developing a healthy muscle mass, including microvasculature, will help mitigate dysglycemic and dyslipidemic fluctuations and improve insulin sensitivity. the overarching purpose of this proposed study is to determine the impact of t1d on human skeletal muscle and its microvasculature over the lifespan in males and females, and its responses to exercise training and detraining.


Eligibility criteria:
inclusion criteria: * age of 18-30 or 45-65 * sedentary or recreationally active, as defined by self-reported activity levels below the recommended 150-minute minimum of moderate-to-vigorous intensity physical activity per week exclusion criteria: * chronic use of anti-inflammatory, glucocorticoid, or other pain-relief medication * history of daily cannabis, tobacco, or nicotine use within six months of study initiation * bmi \>30kg/m2 * prediabetes * type 2 diabetes * health conditions that put the subject at risk to participate in exercise during this study * atypical or grade 2b diabetic sensorimotor polyneuropathy * more than one lifetime event of hospitalization for diabetic ketoacidosis
figure of 8 walk test in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: balance disorder is common in people with ms. as the disease worsens, it is associated with impaired balance, difficulty walking, decreased mobility, and an increased risk of falling. given the prevalence and clinical significance of balance dysfunction in individuals with ms, the assessment of balance has become an important focus in ms clinical practice and research. the figure of 8 walk test is a standard clinical measure used to evaluate the forward walking performance required in daily life. beyond walking straight, turning ability is required in many situations in daily life such as walking around a table, avoiding obstacles and navigating the street. the gait characteristics of walking on a straight and curved road are different. during curved walking, the center of mass of the body shifts to the inner leg as the stance time of the inner leg increases, as opposed to walking on a straight track. compared to other standardized tests, scoring is not dependent on the subjectivity of the examiner, can be administered by a person with minimal training, and requires minimal time, space, and equipment. the test assesses the ability to quickly change direction of movement and is a timed test involving the use of assistive devices.

multiple sclerosis (ms) is a progressive disease of the central nervous system characterized by demyelination and destruction of motor and sensory axons. as the disease worsens, it is associated with impaired balance, difficulty walking, decreased mobility, and an increased risk of falling. the prevalence of balance dysfunction in individuals with ms and given its clinical relevance, the assessment of balance has become an important focus in ms clinical practice and research. the figure of 8 walk test is a standard clinical measure used to evaluate the forward walking performance required in daily life.in the figure of 8 walk test, two cones are placed 1.5 meters apart. the individual stands in the middle of this distance. at the start of the test, he goes around the first cone as fast as he can walk around the first cone, then when he comes to the other starting point, this time around the other cone. the elapsed time is recorded. the aim of the study is to examine the validity and reliability of the 8-shape walking test in ms patients.

Eligibility criteria:
inclusion criteria: * having an edss score of 4 and below, * being between the ages of 18-65 * willingness to participate in the study exclusion criteria: * being pregnant or within the first 3 months after giving birth, * receiving corticosteroid therapy in the last 1 month, * using drugs that will affect walking in the last 1 month

Keywords: multiple scleorsis balance walking